{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05788536",
            "orgStudyIdInfo": {
                "id": "DB-OTO-001"
            },
            "secondaryIdInfos": [
                {
                    "id": "2022-000079-38",
                    "type": "EUDRACT_NUMBER"
                }
            ],
            "organization": {
                "fullName": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            },
            "briefTitle": "A Study of DB-OTO, an Adeno-associated Virus (AAV) Based Gene Therapy, in Children/Infants With Hearing Loss Due to Otoferlin Mutations",
            "officialTitle": "A PHASE 1/2, OPEN-LABEL, MULTICENTER TRIAL WITH A SINGLE ASCENDING DOSE COHORT WITH UNILATERAL INTRACOCHLEAR INJECTION FOLLOWED BY A BILATERAL INJECTION EXPANSION COHORT TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF DB-OTO IN CHILDREN AND INFANTS WITH BIALLELIC hOTOF MUTATIONS",
            "acronym": "CHORD",
            "therapeuticArea": [
                "Other"
            ],
            "study": "a-study-of-db-oto-an-adeno-associated-virus-aav-based-gene-therapy-in-children-infants-with-hearing-loss-due-to-otoferlin-mutations"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-06",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2023-05-12",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2031-04-19",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2031-04-19",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2023-03-15",
            "studyFirstSubmitQcDate": "2023-03-15",
            "studyFirstPostDateStruct": {
                "date": "2023-03-29",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-06-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-06-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Regeneron Pharmaceuticals",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Regeneron is conducting a study of an investigational new drug called DB-OTO. DB-OTO is a gene therapy that is being developed to treat children who have hearing loss due to changes in the otoferlin gene.\n\nThe purpose of this study is to:\n\n* Learn about the safety of DB-OTO\n* Determine how well DB-OTO is tolerated (does not cause ongoing discomfort)\n* Evaluate the efficacy of DB-OTO (how well DB-OTO works)",
            "detailedDescription": "Former Sponsor Decibel Therapeutics"
        },
        "conditionsModule": {
            "conditions": [
                "Congenital Hearing Loss Secondary to Biallelic Mutations of the Otoferlin Gene (OTOF)"
            ],
            "keywords": [
                "DB-OTO",
                "Gene Therapy",
                "Congenital Hearing Loss",
                "Sensorineural Hearing Loss",
                "Auditory Neuropathy",
                "Pediatric",
                "Cochlear Implant",
                "Otoferlin",
                "Deaf",
                "Hard of hearing",
                "Hearing impaired",
                "Hearing disorder",
                "Fully implantable hearing aid",
                "Child",
                "Infant",
                "CHORD"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NON_RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "interventionModelDescription": "DB-OTO will be administered as a single intracochlear injection into one (Part A) or both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 22,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "DB-OTO - Dose Escalation",
                    "type": "EXPERIMENTAL",
                    "description": "Unilateral intracochlear dosing",
                    "interventionNames": [
                        "Genetic: DB-OTO"
                    ]
                },
                {
                    "label": "DB-OTO - Dose Expansion",
                    "type": "EXPERIMENTAL",
                    "description": "Bilateral intracochlear dosing using the dose selected based on safety and efficacy data from the Dose Escalation phase (Part A).",
                    "interventionNames": [
                        "Genetic: DB-OTO"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "GENETIC",
                    "name": "DB-OTO",
                    "description": "DB-OTO will be administered as a single intracochlear injection into one ear (Part A).\n\n* LD Cohort (starting dose)\n* HD Cohort (high dose)",
                    "armGroupLabels": [
                        "DB-OTO - Dose Escalation"
                    ]
                },
                {
                    "type": "GENETIC",
                    "name": "DB-OTO",
                    "description": "DB-OTO will be administered as a single intracochlear injection into both ears (Part B). For bilateral injections (Part B), patients will receive DB-OTO in 1 surgical session.",
                    "armGroupLabels": [
                        "DB-OTO - Dose Expansion"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence and severity of treatment-emergent systemic and local adverse events",
                    "timeFrame": "5 years"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Auditory brainstem response (ABR) - change in intensity threshold (decibels Hearing Level [dB nHL]) across frequency domains",
                    "timeFrame": "5 years"
                },
                {
                    "measure": "Behavioral audiometry with pure-tone audiometry - change in intensity thresholds (dB HL) in treated ear across frequency domains, and speech awareness threshold (SAT) and speech reception threshold (SRT)- change in threshold in treated ear",
                    "timeFrame": "5 years"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Presence of pathogenic or likely pathogenic mutations in both alleles of the OTOF gene.\n2. Patient is \\<18 years of age and of the appropriate age to qualify for enrollment in the corresponding age cohort at the time the parent/legal guardian signs the informed consent form. Participant to provide assent, when applicable\n3. Audiological Criteria:\n\n   US:\n   * Investigator determines that minimal benefit has been provided by amplification of the ear to receive DB-OTO.\n   * Investigator determines the patient meets cochlear implantation criteria in both ears according to the recommended cochlear implant label\n\n   Infants \u226424 months of age:\n   1. Profound sensorineural hearing loss (SNHL; \u2265 90 dB HL) based on behavioral and physiologic measurements (ABR) of inner ear function.\n   2. Outer hair cell function is confirmed by presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO\n\n   Children \\>24 months to \\<18 years of age:\n   1. Profound SNHL (\u2265 90 dB HL) based on physiologic measurements (ABR) of inner ear function AND\n   2. Behavioral open-set word recognition scores of \\< 30% in the ear that would receive DB-OTO\n   3. Outer hair cell function is confirmed by presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO OR\n   4. Presence of a cochlear microphonic in ears to receive DB-OTO.\n\n   UK \\& Spain:\n\n   Infants \u226424 months of age:\n   1. Absence of an ABR neural signal in response to a click stimulus \u226485 dB nHL in the ear(s) to be injected with DB-OTO.\n   2. Presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO.\n\n   Children \\>24 months to \\<18 years of age:\n   1. Absence of an ABR neural signal in response to a click stimulus \u226485 dB nHL in the ear(s) to be injected with DB-OTO.\n   2. Presence of otoacoustic emissions (OAE) in the ear(s) to receive DB-OTO OR\n   3. Presence of a cochlear microphonic in ears to receive DB-OTO.\n4. Willingness of at least 1 parent/legal guardian to consent to vaccinations for the patient in accordance with the country-specific pediatric immunization schedule\n5. No clinically significant laboratory findings on clinical laboratory tests at time of Screening\n6. No evidence that hearing loss is dependent on body temperature\n7. From study start and for the duration of the short-term follow-up period (18 months): Female patients of childbearing potential and fertile males, must agree to use highly effective contraception. Female patients must agree not to become pregnant. Fertile male patients must agree not to father a child or donate sperm.\n\nExclusion Criteria:\n\n1. History or presence of other permanent or untreatable hearing loss conditions.\n2. Prior or current cochlear implants in the ear(s) to be injected with DB-OTO\n3. History of risk factor(s) for auditory neuropathy not caused by OTOF mutations including: prematurity, low birth weight, hyperbilirubinemia, neonatal intensive care unit (NICU) admission, and/or low Apgar scores.\n4. Prior or current history of malignancies.\n5. Prior or current history of meningitis.\n6. History of prior treatment with gene therapy.\n7. Surgical anatomy that would preclude the planned surgical approach as indicated by medical imaging (eg, computed tomography \\[CT\\] or magnetic resonance imaging \\[MRI\\]) in the ear(s) to be injected with DB-OTO.\n\nNote: additional inclusion/exclusion criteria apply, per protocol.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "maximumAge": "17 Years",
            "stdAges": [
                "CHILD"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trials Administrator",
                    "role": "CONTACT",
                    "phone": "844-734-6643",
                    "email": "clinicaltrials@regeneron.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Clinical Trial Management",
                    "affiliation": "Regeneron Pharmaceuticals",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "UCLA Health- Department of Medicine",
                    "status": "RECRUITING",
                    "city": "Los Angeles",
                    "state": "California",
                    "zip": "90095",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Akira Ishiyama, MD",
                            "role": "CONTACT",
                            "email": "aishiyama@mednet.ucla.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 34.05223,
                        "lon": -118.24368
                    }
                },
                {
                    "facility": "The Nemours Foundation d/b/a Nemours Children's Health",
                    "status": "RECRUITING",
                    "city": "Jacksonville",
                    "state": "Florida",
                    "zip": "32207",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Evie Landry, MD",
                            "role": "CONTACT",
                            "email": "Evie.Landry@nemours.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 30.33218,
                        "lon": -81.65565
                    }
                },
                {
                    "facility": "New York Presbyterian Hospital-Columbia University Medical Center",
                    "status": "RECRUITING",
                    "city": "New York",
                    "state": "New York",
                    "zip": "10032",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lawrence R. Lustig, MD",
                            "role": "CONTACT",
                            "email": "lrl2125@cumc.columbia.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.71427,
                        "lon": -74.00597
                    }
                },
                {
                    "facility": "Children's Hospital Medical Center",
                    "status": "NOT_YET_RECRUITING",
                    "city": "Cincinnati",
                    "state": "Ohio",
                    "zip": "45229",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "John Greinwald, MD",
                            "role": "CONTACT",
                            "email": "john.greinwald@cchmc.org"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.12713,
                        "lon": -84.51435
                    }
                },
                {
                    "facility": "Seattle Children's Hospital dba Seattle Children's Research Institute",
                    "status": "RECRUITING",
                    "city": "Seattle",
                    "state": "Washington",
                    "zip": "98105",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jay T. Rubinstein, M.D., Ph.D",
                            "role": "CONTACT",
                            "email": "rubinj@uw.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 47.60621,
                        "lon": -122.33207
                    }
                },
                {
                    "facility": "The Medical College of Wisconsin, Inc.",
                    "status": "RECRUITING",
                    "city": "Milwaukee",
                    "state": "Wisconsin",
                    "zip": "53226",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Caroline Rupcich",
                            "role": "CONTACT",
                            "email": "crupcich@mcw.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 43.0389,
                        "lon": -87.90647
                    }
                },
                {
                    "facility": "Hospital Universitario Insular Materno-Infantil de Las Palmas",
                    "status": "RECRUITING",
                    "city": "Las Palmas de Gran Canaria",
                    "zip": "35016",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Angel Ramos Macias, MD, PhD",
                            "role": "CONTACT",
                            "email": "ramosorl@idecnet.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 28.09973,
                        "lon": -15.41343
                    }
                },
                {
                    "facility": "Hospital Universitario Ram\u00f3n y Cajal",
                    "status": "RECRUITING",
                    "city": "Madrid",
                    "zip": "28034",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Ruben Polo L\u00f3pez",
                            "role": "CONTACT",
                            "email": "rubenpolo1979@gmail.com"
                        }
                    ],
                    "geoPoint": {
                        "lat": 40.4165,
                        "lon": -3.70256
                    }
                },
                {
                    "facility": "Clinica Universidad de Navarra",
                    "status": "RECRUITING",
                    "city": "Pamplona",
                    "zip": "31008",
                    "country": "Spain",
                    "contacts": [
                        {
                            "name": "Manuel Jesus Manrique Rodriguez",
                            "role": "CONTACT",
                            "email": "mmanrique@unav.es"
                        }
                    ],
                    "geoPoint": {
                        "lat": 42.81687,
                        "lon": -1.64323
                    }
                },
                {
                    "facility": "Cambridge University Hospitals NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "Cambridge",
                    "zip": "CB2 0QQ",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Manohar Bance, FRCSC",
                            "role": "CONTACT",
                            "email": "mlb59@cam.ac.uk"
                        }
                    ],
                    "geoPoint": {
                        "lat": 52.2,
                        "lon": 0.11667
                    }
                },
                {
                    "facility": "Great Ormond Street Hospital for Children- NHS Foundation Trust",
                    "status": "RECRUITING",
                    "city": "London",
                    "zip": "WC1N 3JH",
                    "country": "United Kingdom",
                    "contacts": [
                        {
                            "name": "Robert Nash, FRCS",
                            "role": "CONTACT",
                            "email": "r.nash@ucl.ac.uk"
                        }
                    ],
                    "geoPoint": {
                        "lat": 51.50853,
                        "lon": -0.12574
                    }
                }
            ]
        },
        "referencesModule": {
            "seeAlsoLinks": [
                {
                    "label": "Patients, Caregivers \\& HCPs: Contribute to Genetic Hearing Loss Research",
                    "url": "https://portal.sanogenetics.com/study/genetic-hearing-loss-trials"
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES",
            "description": "All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing",
            "infoTypes": [
                "STUDY_PROTOCOL",
                "SAP",
                "ICF",
                "CSR",
                "ANALYTIC_CODE"
            ],
            "timeFrame": "When Regeneron has received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication, has made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry), has the legal authority to share the data, and has ensured the ability to protect participant privacy.",
            "accessCriteria": "Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf",
            "url": "https://vivli.org/"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000034381",
                    "term": "Hearing Loss"
                },
                {
                    "id": "D000003638",
                    "term": "Deafness"
                }
            ],
            "ancestors": [
                {
                    "id": "D000006311",
                    "term": "Hearing Disorders"
                },
                {
                    "id": "D000004427",
                    "term": "Ear Diseases"
                },
                {
                    "id": "D000010038",
                    "term": "Otorhinolaryngologic Diseases"
                },
                {
                    "id": "D000012678",
                    "term": "Sensation Disorders"
                },
                {
                    "id": "D000009461",
                    "term": "Neurologic Manifestations"
                },
                {
                    "id": "D000009422",
                    "term": "Nervous System Diseases"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M12307",
                    "name": "Neoplasm Metastasis",
                    "relevance": "LOW"
                },
                {
                    "id": "M24420",
                    "name": "Hearing Loss",
                    "asFound": "Hearing Loss",
                    "relevance": "HIGH"
                },
                {
                    "id": "M6840",
                    "name": "Deafness",
                    "asFound": "Hearing Loss",
                    "relevance": "HIGH"
                },
                {
                    "id": "M9407",
                    "name": "Hearing Loss, Sensorineural",
                    "relevance": "LOW"
                },
                {
                    "id": "M17522",
                    "name": "Virus Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9400",
                    "name": "Hearing Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M7601",
                    "name": "Ear Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M12961",
                    "name": "Otorhinolaryngologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M15490",
                    "name": "Sensation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M12404",
                    "name": "Neurologic Manifestations",
                    "relevance": "LOW"
                },
                {
                    "id": "T547",
                    "name": "Auditory Neuropathy Spectrum Disorder",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC09",
                    "name": "Ear, Nose, and Throat Diseases"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        }
    },
    "hasResults": false
}